UBS on Tuesday upgraded British alternative assets manager Intermediate Capital Group (ICG.L) to buy from neutral, while maintaining its price target at 21.50 pounds sterling.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Apogee Therapeutics (APGE) has an average rating of overweight and mean price target of $122.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $132.63, Change: $+42.25, Percent Change: +46.75%
Apogee Therapeutics (APGE) has an average rating of overweight and mean price target of $119.07, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $132.65, Change: $+42.27, Percent Change: +46.76%
(Updates with the analyst's commentary.)Seaport Global upgraded BWX Technologies (BWXT) to buy from neutral, citing the company's acquisition of Precision Components Group after a "strong" fiscal Q1.PCG 2025 revenue was about $125 million and it paid about $200 million for the firm, the brokerage said, citing BWX management.PCG is an authorized nuclear component manufacturer and certified for aerospace and defense quality-management, Seaport said.BWX Technologies has an average rating of overweight and mean price target of $240.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $212.56, Change: $+7.16, Percent Change: +3.49%